CardioFocus
CardioFocus is a privately held medical device company that develops Pulsed Field Ablation (PFA) catheter and generator systems for treating cardiac arrhythmias, primarily atrial fibrillation, serving electrophysiologists and EP hospitals in the US, EU, Japan, and China.
- Company typePrivate
- Founded2000
- HeadquartersMarlborough, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What CardioFocus does
CardioFocus is a privately held medical device company headquartered in Marlborough, Massachusetts (Delaware-incorporated), developing Pulsed Field Ablation (PFA) systems for the treatment of cardiac arrhythmias, with a primary focus on atrial fibrillation. The company's core technology combines proprietary waveform science — most notably the WAVE1 monopolar biphasic waveform — with co-engineered catheter and generator platforms. Its portfolio includes the commercially available Centauri System (CE-marked in select EU countries), the legacy FDA-approved HeartLight X3 endoscopic ablation system, and three investigational next-generation systems: QuickShot Nav (large-area focal PFA catheter with integrated mapping), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular generator designed to power multiple catheter types). The company reports over 10,000 patients treated worldwide with the HeartLight platform and serves electrophysiologists performing pulmonary vein isolation procedures.
CardioFocus operates an enterprise field sales model targeting hospitals and electrophysiology labs, supplemented by a network of regional distribution partners for international markets: Japan Lifeline (Japan, since 2015 and deepened via a 2025 strategic alliance), MicroPort CRM (Spain and Portugal), China Grand Pharmaceutical (China), and BIOTRONIK (European expansion, 2024). The company sells hardware — ablation catheters, generators, and accessories — through quote-based hospital procurement processes, and generates incremental revenue through distribution and licensing arrangements with regional partners. Pricing is not publicly disclosed.
The company has raised over $200 million cumulatively since inception across multiple venture, debt, and equity rounds, including a $55 million financing in 2019 led by Kennedy Lewis Investment Management and SEC Form D filings of approximately $50 million (2022) and $31.76 million (2023). Recent strategic actions include the January 2024 acquisition of the Electrophysiology Division of Galvanize Therapeutics to expand PFA intellectual property, and a series of 2024–2026 partnerships with Stereotaxis (robotic PFA), LUMA Vision (4D imaging-guided ablation), and the expansion of CE Mark and US IDE clinical programs across Europe and the United States.
CardioFocus firmographics
Firmographics- Name
- CardioFocus
- Legal name
- CardioFocus, Inc.
- Website
- https://cardiofocus.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- CardioFocus is a privately held medical device company that develops Pulsed Field Ablation (PFA) catheter and generator systems for treating cardiac arrhythmias, primarily atrial fibrillation, serving electrophysiologists and EP hospitals in the US, EU, Japan, and China.
- Ownership category
- akta.pro rank
CardioFocus industry classification
Industry- Product category
- Cardiac Electrophysiology Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Electrophysiology Mapping & Ablation Systems (HLAHAFAD)
- akta.pro secondary industry
- Electrophysiology (Heart Rhythm) (HLAKABAC)
Keywords
Where CardioFocus is headquartered
LocationHeadquarters
- HQ city
- Marlborough
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
CardioFocus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Revenue model
- PFA Catheter Systems: CardioFocus generates revenue from the sale of pulsed field ablation catheter systems including the Centauri System (CE-marked, commercially available in EU) and investigational systems (QuickShot Nav, OptiShot, CardioWave). Revenue comes from selling ablation catheters, generators, and associated accessories to hospitals and electrophysiology labs.
- Distribution Partnerships: Revenue generated through distribution agreements with regional partners including Japan Lifeline (Japan distribution), MicroPort CRM (Spain and Portugal), China Grand Pharmaceutical (China), and BIOTRONIK (European expansion). Partners distribute CardioFocus products in their respective territories.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels5 records
CardioFocus product offering
Product offeringCore offering
CardioFocus develops and manufactures pulsed field ablation (PFA) catheter systems and generators for treating cardiac arrhythmias, primarily atrial fibrillation. Its portfolio includes the CE-marked Centauri System (open-platform focal PFA with proprietary WAVE1 waveform) and investigational next-generation systems including QuickShot Nav (large-area focal catheter with map-and-ablate capability), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular multi-catheter generator). The products are sold to hospitals and electrophysiology labs for pulmonary vein isolation procedures.
Product overview
CardioFocus develops a portfolio of Pulsed Field Ablation (PFA) systems for treating cardiac arrhythmias, particularly atrial fibrillation. The portfolio includes the CE-marked Centauri System (open-platform focal PFA with three selectable doses and compatibility with major mapping systems), alongside next-generation investigational systems: QuickShot Nav (large-area focal catheter), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular multi-catheter generator). The company previously offered the HeartLight laser balloon system, which has been succeeded by the PFA portfolio. All systems are designed for pulmonary vein isolation procedures and integrate with established electrophysiology lab workflows.
Differentiator
Problem solved
Functional benefit
Brands
- Centauri: CE-marked open-platform pulsed field ablation system with custom monopolar waveform for cardiac tissue ablation.
- QuickShot Nav
- OptiShot
- CardioWave
- HeartLight
Products and services
- Centauri System An open-platform pulsed field ablation system that integrates into established electrophysiology workflows, delivering a custom monopolar waveform (WAVE1) to create durable lesions safely and efficiently. CE-marked and available in select EU countries, with compatibility across major mapping systems (EnSite X, Carto 3, Rhythmia HDx) and contact force catheters.
- QuickShot Nav A versatile large-area focal PFA catheter designed to map and ablate with a single, integrated device, uniting mapping and ablation into one streamlined workflow for addressing complex cardiac arrhythmias.
- OptiShot An ultra-compliant pulsed field ablation balloon with direct endoscopic visualization, enabling circumferential therapy from a single position with a single energy application per vein for pulmonary vein isolation, with anatomy-adaptive balloon architecture.
- CardioWave System A modular, next-generation PFA generator engineered to power multiple catheter types and clinical applications from a single system, built on proven Centauri technology.
- HeartLight Endoscopic Ablation System Legacy laser balloon ablation system for treatment of atrial fibrillation, FDA-approved in 2016 and superseded by the company's PFA portfolio.
Quantifiable outcome
- 89% PV isolation at 3 months using Centauri System across three compatible ablation catheters
- +5 more outcomes
Companies that use CardioFocus
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles1 record
CardioFocus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration9 records
Feature7 records
CardioFocus partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered strategic, major and core.
- LUMA VisionstrategicClinical study collaboration in which LUMA Vision's VERAFEYE 4D Imaging Platform was used with CardioFocus ablation systems. Study demonstrated VERAFEYE's ability to integrate high-resolution intracardiac imaging with CardioFocus PFA technology, enabling streamlined two-catheter ablation workflow.
- StereotaxismajorCollaboration to advance robotic Pulsed Field Ablation (PFA) technology for cardiac arrhythmias. Joint effort aims to accelerate commercialization of combined robotic PFA system, with preclinical testing showing promising results.
- BIOTRONIKmajorPartnership to expand pulsed field ablation access in Europe. BIOTRONIK will distribute CardioFocus PFA products to expand market reach across European territories.
- Japan LifelinecoreStrategic alliance to advance differentiated PFA system in Japan. Japan Lifeline has been a distribution partner for CardioFocus HeartLight system since 2015, with expanded partnership in 2018 and 2021. The partnership covers distribution of PFA products in Japan.
- Galvanize TherapeuticscoreCardioFocus acquired the Electrophysiology Division of Galvanize Therapeutics, including key intellectual property assets that strengthen CardioFocus's PFA technology portfolio.
- China Grand PharmaceuticalmajorAgreement to bring HeartLight X3 System to China. China Grand Pharmaceutical serves as distribution partner for the Chinese market.
- MicroPort CRMcoreExpanded distribution partnership to include Spain and Portugal for HeartLight System distribution. MicroPort CRM covers key European markets.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
CardioFocus competitors and assessment
Company assessmentRegional players
- BIOTRONIK: European distribution partner for CardioFocus PFA products (announced July 2024) and a broader cardiac rhythm management device manufacturer. Comparable as a CRM and ablation-adjacent player with strong European EP footprint that channels CardioFocus into hospitals.
- MicroPort CRM: Distribution partner for CardioFocus HeartLight in Spain and Portugal (announced 2021) and broader CRM/cardiac device manufacturer. Comparable as a regional EP-focused player serving Iberian markets where CardioFocus relies on partner-led commercialization.
- Japan Lifeline: Japanese distribution partner for CardioFocus HeartLight since 2015 and now strategic PFA alliance partner (February 2025). Comparable as a regional EP/cardiac rhythm distributor addressing the Japanese market CardioFocus does not serve directly.
Direct peers
- Medtronic: Direct competitor via PulseSelect single-shot PFA catheter and the Affera mapping-and-ablation platform acquired in 2022. Medtronic is a major incumbent with global EP sales force and bundled mapping (CardioInsight) competing head-to-head in the PFA category.
- Boston Scientific: Direct competitor through its Farapulse pulsed field ablation system, which has been one of the earliest commercialized PFA platforms globally. Boston Scientific's scale, US sales force, and integrated mapping (OPAL HDx) compete directly with CardioFocus's Centauri System in EP labs.
- Johnson & Johnson (Biosense Webster): Direct competitor with the Varipulse pulsed field ablation catheter and CARTO 3 mapping system — a dominant EP franchise worldwide. CardioFocus's Centauri is explicitly compatible with CARTO 3, meaning J&J is both a partner-enabler and a direct competitor in PFA.
- Abbott: Direct competitor through Abbott's TactiFlex Sensor Enabled and Volt PFA catheters targeting atrial fibrillation ablation. Abbott's EnSite X mapping system is a key integration partner for CardioFocus's Centauri, mirroring the J&J dynamic of partnership plus competition.
Emerging players
- Acutus Medical: Emerging player in electrophysiology with novel mapping technology and ablation catheter development, including PFA-related programs. Compares to CardioFocus as a smaller, technology-focused EP innovator competing against larger integrated incumbents.
- Stereotaxis: Robotic magnetic navigation ablation partner of CardioFocus (announced October 2025) developing robotic PFA workflows. Comparable as an EP technology enabler serving the same electrophysiology lab customers CardioFocus targets.
- Adagio Medical: Emerging player developing ultra-low temperature cryoablation and pulsed field technologies for atrial fibrillation. Adagio's iCLAS catheter and cryo-PFA approach represent an alternative single-shot strategy, partially overlapping with CardioFocus's OptiShot balloon platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks1 record
Key highlights7 records
Customer concentration
CardioFocus social profiles
Digital presenceCardioFocus compliance and trust
Trust signalCompliance2 records
CardioFocus financial estimates
Financial estimateRevenue estimate
Valuation estimate
CardioFocus leadership team
Management profileNumber of profiles
Profiles6 records
CardioFocus subsidiaries and ownership
Company hierarchySubsidiaries1 record
CardioFocus funding detail
Funding detailFunding overview
Funding rounds19 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CardioFocus M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CardioFocus
What does CardioFocus do?
CardioFocus develops and manufactures pulsed field ablation (PFA) catheter systems and generators for treating cardiac arrhythmias, primarily atrial fibrillation. Its portfolio includes the CE-marked Centauri System (open-platform focal PFA with proprietary WAVE1 waveform) and investigational next-generation systems including QuickShot Nav (large-area focal catheter with map-and-ablate capability), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular multi-catheter generator). The products are sold to hospitals and electrophysiology labs for pulmonary vein isolation procedures.
Is CardioFocus a public or private company?
CardioFocus is a private company. It is classified as venture growth investor backed and is currently operating.
When was CardioFocus founded?
CardioFocus was founded in 2000. It employs 51 to 100 people.
Where is CardioFocus based?
CardioFocus is headquartered in Marlborough, United States, in the North America region.
How does CardioFocus make money?
Two revenue lines are on record. PFA Catheter Systems are the primary driver. The others are distribution Partnerships.
Who are CardioFocus's main competitors?
Regional players on record are BIOTRONIK, MicroPort CRM and Japan Lifeline. Direct peers are Medtronic, Boston Scientific, Johnson & Johnson (Biosense Webster) and Abbott. Emerging players are Acutus Medical, Stereotaxis and Adagio Medical.
Does CardioFocus have an API?
No public API is recorded for CardioFocus.
What industry is CardioFocus in?
CardioFocus's product category is Cardiac Electrophysiology Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3841.